Sale!

Buy Verzenio/Verzenios (abemaciclib)

$1,932.00 $1,732.00

Verzenio/Verzenios (abemaciclib)

Verzenio (abemaciclib) is a medication indicated for the treatment of women with HR-positive, HER2-negative advanced or metastatic breast cancer.

  • 28 tablets of 50 mg $1,732

Category:

Description

What is Verzenio (abemaciclib)?

Verzenio (abemaciclib) is a kinase inhibitor indicated to treat HR+/HER2 (hormone receptor positive/human epidermal growth factor receptor 2 negative) metastatic breast cancer[1]. It is also used for the treatment of postmenopausal women whose cancer has progressed after hormonal therapy or chemotherapy[1].

Who is Verzenio (abemaciclib) for?

Verzenio (abemaciclib) is for patients with a type of breast cancer called HR+/HER2(hormone receptor positive/human epidermal growth factor receptor 2 negative)

[1]:

  • as initial endocrine-based therapy in combination with an aromatase inhibitor for the treatment of postmenopausal women

  • in women whose disease has progressed after hormonal therapy, in combination with fulvestrant

  • in women whose disease has progressed after hormone therapy and prior chemotherapy as a monotherapy (not in combination with other medicines).

How does Verzenio (abemaciclib) work?

Verzenio is in a class of drugs known as CDK4 & 6 inhibitors2. CDK4 & 6 proteins control how fast cells grow and divide. CDK4 & 6 proteins are found in both normal and cancer cells[2]. They are overactive in patients with metastatic breast cancer, causing cells to grow and divide uncontrollably[2]. This leads to the spread of cancer[2].

Verzenio works to stop these proteins and cells as they are moving to grow and divide[2]. It slows down the cell growth and division, which causes cancer cells to become inactive or even die. In preclinical studies, continuous exposure to Verzenio slowed down CDK4 & 6 proteins, which delayed cancer cells from growing and dividing[2].

Where has Verzenio (abemaciclib) been approved?

Verzenio (abemaciclib) was approved for the treatment of patients with metastatic breast cancer by:

  • Food and Drug Administration (FDA), USA:

    • September 28, 2017[4], as second-line treatment

    • February 26, 2018[2,3], as first-line treatment.
  • European Medical Agency (EMA), European Union, September 27, 2018[5]
  • Health Canada, April 4, 2019[6]
  • Therapeutic Goods Administration (TGA, under the Australia-Canada-Singapore-Switzerland [ACSS] Consortium’s New Chemical Entities Work Sharing Initiative), Australia, April 9, 2019[7]

Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.

How is Verzenio (abemaciclib) taken?

Verzenio (abemaciclib) is a tablet that is taken orally, with or without food[1]. The standard dosage is:

  • 150 mg twice daily as a starting dose in combination with fulvestrant[1]

  • 200 mg twice daily as a starting dose as monotherapy[1]

Dosing interruption and/or dose reductions may be required based on individual safety and tolerability[1].

Warning:

  • Patients who experience diarrhea should alert their healthcare provider, initiate antidiarrheal therapy, and increase oral fluids[1].

  • A patient’s blood counts should also be monitored prior to the start of Verzenio (abemaciclib) therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated[1].

  • Increases in serum transaminase (liver enzymes) levels have been observed in patients taking Verzenio (abemaciclib). Liver function tests (LFTs) should be performed before initiating treatment. LFTs should be monitored every two weeks for the first two months, monthly for the next 2 months, and as clinically indicated[1].

  • Patients should be monitored for signs and symptoms of thrombosis and pulmonary embolism and treat as medically appropriate[1].

Complete information about Verzenio (abemaciclib) dosage and administration can be found in the official prescribing information listed in our references section[1].

Note: Please consult with your treating doctor for personalised dosing.

Are there any known side effects or adverse reactions of Verzenio (abemaciclib)?

Common adverse reactions

The most common adverse reactions listed in the prescribing information include[1]:

  • diarrhea

  • neutropenia

  • nausea

  • abdominal pain

  • infections

  • fatigue

  • anemia

  • leukopenia

  • decreased appetite

  • vomiting

  • headache

  • thrombocytopenia.

Serious adverse reactions

The serious adverse reactions listed in the prescribing information include[1]:

  • diarrhea

  • alterations in a patient’s blood counts

  • increases in liver enzymes

  • thrombosis and pulmonary embolism.

Use in specific populations

  • Pregnant women: Verzenio (abemaciclib) can cause fetal harm when administered to a pregnant woman, it is advised to avoid pregnancies and breast feeding[1].

  • Breastfeeding women: There are no data on the presence of abemaciclib in human milk, or its effects on the breastfed child or on milk production1. Because of the potential for serious adverse reactions in breastfed infants, it’s advised that lactating women do not breastfeed during treatment and for at least 3 weeks after the last dose[1].

  • Women with reproductive potential: Verzenio (abemaciclib) can cause fetal harm when administered to a pregnant woman Pregnancy testing is recommended for females of reproductive potential prior to initiating treatment with Verzenio (abemaciclib)1. Women who could possibly become pregnant (have reproductive potential) should be advised to use effective contraception during treatment and for at least 3 weeks after the last dose[1].

  • Men: Based on findings in animals, Verzenio (abemaciclib) may impair fertility in males of reproductive potential[1].

  • Pediatric use (children): The safety and effectiveness of Verzenio (abemaciclib) have not been established in children[1].

  • Geriatric patients (elderly patients): Of the 441 patients who received Verzenio (abemaciclib) in the MONARCH 2 trial, 35% were 65 years of age or older and 9% were 75 years of age or older. Of the 132 patients who received Verzenio (abemaciclib) in MONARCH 1, 32% were 65 years of age or older and 8% were 75 years of age or older. No overall differences in safety or effectiveness of Verzenio (abemaciclib) were observed between older patients and younger patients[1].

  • Renal impairment (kidney problems): No dosage adjustment is required for patients with mild or moderate renal impairment[1].

  • Hepatic impairment (liver problems): No dosage adjustments are necessary in patients with mild or moderate hepatic impairment (Child-Pugh A or B). Reduce the dosing frequency when administering Verzenio (abemaciclib) to patients with severe hepatic impairment (Child-Pugh C)[1].

  • 28 tablets of 50 mg $1,732

Reviews

There are no reviews yet.

Be the first to review “Buy Verzenio/Verzenios (abemaciclib)”

Your email address will not be published. Required fields are marked *